Log in

Relevant bibliographies by topics / Cell-based immunotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Cell-based immunotherapy.

Journal articles on the topic 'Cell-based immunotherapy'

Author: Grafiati

Published: 7 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cell-based immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H. Kim Lyerly. "Dendritic Cell-Based Immunotherapy." International Reviews of Immunology 25, no. 5-6 (January 2006): 377–413. http://dx.doi.org/10.1080/08830180600992456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sabado, Rachel L., Sreekumar Balan, and Nina Bhardwaj. "Dendritic cell-based immunotherapy." Cell Research 27, no. 1 (December 27, 2016): 74–95. http://dx.doi.org/10.1038/cr.2016.157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Razzak, Mina. "New cell-based immunotherapy?" Nature Reviews Urology 9, no. 3 (February 21, 2012): 122. http://dx.doi.org/10.1038/nrurol.2012.18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chang, Kiyuk, Jie-Young Song, and Dae-Seog Lim. "Tolerogenic dendritic cell-based immunotherapy." Oncotarget 8, no. 53 (October 17, 2017): 90630–31. http://dx.doi.org/10.18632/oncotarget.21867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Golán, Irene, Laura Rodríguez de la Fuente, and Jose Costoya. "NK Cell-Based Glioblastoma Immunotherapy." Cancers 10, no. 12 (December 18, 2018): 522. http://dx.doi.org/10.3390/cancers10120522.

Full text

Abstract:

Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges.

APA, Harvard, Vancouver, ISO, and other styles

6

Wennhold, Kerstin, Alexander Shimabukuro-Vornhagen, and Michael von Bergwelt-Baildon. "B Cell-Based Cancer Immunotherapy." Transfusion Medicine and Hemotherapy 46, no. 1 (2019): 36–46. http://dx.doi.org/10.1159/000496166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Urbonas, Vincas, Giedre Smailyte, Greta V. Urbonaite, Audrius Dulskas, Neringa Burokiene, and Vytautas Kasiulevicius. "Natural killer cell-based immunotherapy." Melanoma Research 29, no. 2 (April 2019): 208–11. http://dx.doi.org/10.1097/cmr.0000000000000552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kadowaki, Norimitsu, and Toshio Kitawaki. "V. Dendritic Cell-based Immunotherapy." Nihon Naika Gakkai Zasshi 108, no. 7 (July 10, 2019): 1391–96. http://dx.doi.org/10.2169/naika.108.1391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Stagg, J., and M. J. Smyth. "NK cell-based cancer immunotherapy." Drug News & Perspectives 20, no. 3 (2007): 155. http://dx.doi.org/10.1358/dnp.2007.20.3.1092096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Buckler, Lee. "Rise of Cell-Based Immunotherapy." Genetic Engineering & Biotechnology News 33, no. 5 (March 2013): 12–13. http://dx.doi.org/10.1089/gen.33.5.05.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

ENGLEMAN, E. "Dendritic cell-based cancer immunotherapy." Seminars in Oncology 30 (June 2003): 23–29. http://dx.doi.org/10.1016/s0093-7754(03)00229-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Zhang, Hao, Li Yang, Tingting Wang, and Zhen Li. "NK cell-based tumor immunotherapy." Bioactive Materials 31 (January 2024): 63–86. http://dx.doi.org/10.1016/j.bioactmat.2023.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Song, Min-Seon, Ji-Hee Nam, Kyung-Eun Noh, and Dae-Seog Lim. "Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration." Journal of Immunology Research 2024 (April 8, 2024): 1–11. http://dx.doi.org/10.1155/2024/7827246.

Full text

Abstract:

Dendritic cells (DCs) are specialized antigen-presenting cells that are crucial for maintaining self-tolerance, initiating immune responses against pathogens, and patrolling body compartments. Despite promising aspects, DC-based immunotherapy faces challenges that include limited availability, immune escape in tumors, immunosuppression in the tumor microenvironment, and the need for effective combination therapies. A further limitation in DC-based immunotherapy is the low population of migratory DC (around 5%–10%) that migrate to lymph nodes (LNs) through afferent lymphatics depending on the LN draining site. By increasing the population of migratory DCs, DC-based immunotherapy could enhance immunotherapeutic effects on target diseases. This paper reviews the importance of DC migration and current research progress in the context of DC-based immunotherapy.

APA, Harvard, Vancouver, ISO, and other styles

14

Terrén, Iñigo, Ane Orrantia, Idoia Mikelez-Alonso, Joana Vitallé, Olatz Zenarruzabeitia, and Francisco Borrego. "NK Cell-Based Immunotherapy in Renal Cell Carcinoma." Cancers 12, no. 2 (January 29, 2020): 316. http://dx.doi.org/10.3390/cancers12020316.

Full text

Abstract:

Natural killer (NK) cells are cytotoxic lymphocytes that are able to kill tumor cells without prior sensitization. It has been shown that NK cells play a pivotal role in a variety of cancers, highlighting their relevance in tumor immunosurveillance. NK cell infiltration has been reported in renal cell carcinoma (RCC), the most frequent kidney cancer in adults, and their presence has been associated with patients’ survival. However, the role of NK cells in this disease is not yet fully understood. In this review, we summarize the biology of NK cells and the mechanisms through which they are able to recognize and kill tumor cells. Furthermore, we discuss the role that NK cells play in renal cell carcinoma, and review current strategies that are being used to boost and exploit their cytotoxic capabilities.

APA, Harvard, Vancouver, ISO, and other styles

15

Ghoneim, Hazem E., Anthony E. Zamora, Paul G. Thomas, and Ben A. Youngblood. "Cell-Intrinsic Barriers of T Cell-Based Immunotherapy." Trends in Molecular Medicine 22, no. 12 (December 2016): 1000–1011. http://dx.doi.org/10.1016/j.molmed.2016.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Gitlitz, Barbara J., Robert A. Figlin, Allan J. Pantuck, and Arie S. Belldegrun. "Dendritic cell-based immunotherapy of renal cell carcinoma." Current Urology Reports 2, no. 1 (February 2001): 46–52. http://dx.doi.org/10.1007/s11934-001-0025-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Janikashvili, Nona, Nicolas Larmonier, and Emmanuel Katsanis. "Personalized dendritic cell-based tumor immunotherapy." Immunotherapy 2, no. 1 (January 2010): 57–68. http://dx.doi.org/10.2217/imt.09.78.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Charles, Ronald, Lina Lu, Shiguang Qian, and John J. Fung. "Stromal cell-based immunotherapy in transplantation." Immunotherapy 3, no. 12 (December 2011): 1471–85. http://dx.doi.org/10.2217/imt.11.132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cornelissen, Robin, Lysanne A. Lievense, Marlies E. Heuvers, Alexander P. Maat, Rudi W. Hendriks, Henk C. Hoogsteden, Joost P. Hegmans, and Joachim G. Aerts. "Dendritic cell-based immunotherapy in mesothelioma." Immunotherapy 4, no. 10 (October 2012): 1011–22. http://dx.doi.org/10.2217/imt.12.108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Zitvogel, Laurence, Eric Angevin, and Thomas Tursz. "Dendritic cell-based immunotherapy of cancer." Annals of Oncology 11 (2000): 199–206. http://dx.doi.org/10.1093/annonc/11.suppl_3.199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Schaar, Bruce, Venkatesh Krishnan, Supreeti Tallapragada, and Oliver Dorigo. "Cell-based immunotherapy in gynecologic malignancies." Current Opinion in Obstetrics and Gynecology 30, no. 1 (February 2018): 23–30. http://dx.doi.org/10.1097/gco.0000000000000433.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Schaar, Bruce, Venkatesh Krishnan, Supreeti Tallapragada, Anita Chanana, and Oliver Dorigo. "Cell-based immunotherapy in gynecologic malignancies." Current Opinion in Obstetrics and Gynecology 31, no. 1 (February 2019): 43–48. http://dx.doi.org/10.1097/gco.0000000000000518.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fang, Fang, Weihua Xiao, and Zhigang Tian. "NK cell-based immunotherapy for cancer." Seminars in Immunology 31 (June 2017): 37–54. http://dx.doi.org/10.1016/j.smim.2017.07.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Tran, Tuan Hiep, Thi Thu Phuong Tran, Hanh Thuy Nguyen, Cao Dai Phung, Jee-Heon Jeong, Martina H. Stenzel, Sung Giu Jin, Chul Soon Yong, Duy Hieu Truong, and Jong Oh Kim. "Nanoparticles for dendritic cell-based immunotherapy." International Journal of Pharmaceutics 542, no. 1-2 (May 2018): 253–65. http://dx.doi.org/10.1016/j.ijpharm.2018.03.029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kamat, Kalika, Venkatesh Krishnan, Jonathan S. Berek, and Oliver Dorigo. "Cell-based immunotherapy in gynecologic malignancies." Current Opinion in Obstetrics & Gynecology 33, no. 1 (December 3, 2020): 13–18. http://dx.doi.org/10.1097/gco.0000000000000676.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Lo Presti, Elena, Anna Maria Corsale, Francesco Dieli, and Serena Meraviglia. "γδ cell-based immunotherapy for cancer." Expert Opinion on Biological Therapy 19, no. 9 (June 23, 2019): 887–95. http://dx.doi.org/10.1080/14712598.2019.1634050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Höltl, Lorenz, Claudia Zelle-Rieser, Hubert Gander, Christine Papesh, Reinhold Ramoner, Georg Bartsch, and Martin Thurnher. "Dendritic cell-based immunotherapy for metastatic renal cell cancer." European Urology Supplements 1, no. 1 (January 2002): 110. http://dx.doi.org/10.1016/s1569-9056(02)80423-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Fang, Fang, Wei Wang, Minhua Chen, Zhigang Tian, and Weihua Xiao. "Technical advances in NK cell-based cellular immunotherapy." Cancer Biology & Medicine 16, no. 4 (November 1, 2019): 647–54. http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0187.

Full text

Abstract:

Natural killer (NK) cells represent a promising future for tumor immunotherapy because of their unique biological functions and characteristics. This review focuses on technical advances in NK cell-based cellular immunotherapy and summarizes the developments of recent years in cell sources, genetic modification, manufacturing systems, clinical programs, and outcomes. Future prospects and challenges in NK cell immunotherapy are also discussed, including off-the-shelf NK cell exploitation, automatic and closed manufacturing systems, cryopreservation, and therapies involving regulatory checkpoints.

APA, Harvard, Vancouver, ISO, and other styles

29

Ulivieri, Cristina, and Cosima T. Baldari. "T-cell-based immunotherapy of autoimmune diseases." Expert Review of Vaccines 12, no. 3 (March 2013): 297–310. http://dx.doi.org/10.1586/erv.12.146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

A. Rabinovich, Brian, and Caius G. Radu. "Imaging Adoptive Cell Transfer Based Cancer Immunotherapy." Current Pharmaceutical Biotechnology 11, no. 6 (September 1, 2010): 672–84. http://dx.doi.org/10.2174/138920110792246528.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Salgaller, M. L., B. A. Tjoa, P. A. Lodge, H. Ragde, G. Kenny, A. Boynton, and G. P. Murphy. "Dendritic Cell-Based Immunotherapy of Prostate Cancer." Critical Reviews™ in Immunology 18, no. 1-2 (1998): 109–19. http://dx.doi.org/10.1615/critrevimmunol.v18.i1-2.120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Della Chiesa, Mariella, Chiara Setti, Chiara Giordano, Valentina Obino, Marco Greppi, Silvia Pesce, Emanuela Marcenaro, et al. "NK Cell-Based Immunotherapy in Colorectal Cancer." Vaccines 10, no. 7 (June 28, 2022): 1033. http://dx.doi.org/10.3390/vaccines10071033.

Full text

Abstract:

Human Natural Killer (NK) cells are all round players in immunity thanks to their powerful and immediate response against transformed cells and the ability to modulate the subsequent adaptive immune response. The potential of immunotherapies based on NK cell involvement has been initially revealed in the hematological setting but has inspired the design of different immune tools to also be applied against solid tumors, including colorectal cancer (CRC). Indeed, despite cancer prevention screening plans, surgery, and chemotherapy strategies, CRC is one of the most widespread cancers and with the highest mortality rate. Therefore, further efficient and complementary immune-based therapies are in urgent need. In this review, we gathered the most recent advances in NK cell-based immunotherapies aimed at fighting CRC, in particular, the use of monoclonal antibodies targeting tumor-associated antigens (TAAs), immune checkpoint blockade, and adoptive NK cell therapy, including NK cells modified with chimeric antigen receptor (CAR-NK).

APA, Harvard, Vancouver, ISO, and other styles

33

Zhou, Yang, Tiffany Husman, Xinjian Cen, Tasha Tsao, James Brown, Aarushi Bajpai, Miao Li, Kuangyi Zhou, and Lili Yang. "Interleukin 15 in Cell-Based Cancer Immunotherapy." International Journal of Molecular Sciences 23, no. 13 (June 30, 2022): 7311. http://dx.doi.org/10.3390/ijms23137311.

Full text

Abstract:

Cell-based cancer immunotherapy, such as chimeric antigen receptor (CAR) engineered T and natural killer (NK) cell therapies, has become a revolutionary new pillar in cancer treatment. Interleukin 15 (IL-15), a potent immunostimulatory cytokine that potentiates T and NK cell immune responses, has demonstrated the reliability and potency to potentially improve the therapeutic efficacy of current cell therapy. Structurally similar to interleukin 2 (IL-2), IL-15 supports the persistence of CD8+ memory T cells while inhibiting IL-2-induced T cell death that better maintains long-term anti-tumor immunity. In this review, we describe the biology of IL-15, studies on administrating IL-15 and/or its derivatives as immunotherapeutic agents, and IL-15-armored immune cells in adoptive cell therapy. We also discuss the advantages and challenges of incorporating IL-15 in cell-based immunotherapy and provide directions for future investigation.

APA, Harvard, Vancouver, ISO, and other styles

34

Tjoa, B. A., P. A. Lodge, M. L. Salgaller, A. L. Boynton, and G. P. Murphy. "Dendritic cell-based immunotherapy for prostate cancer." CA: A Cancer Journal for Clinicians 49, no. 2 (March 1, 1999): 117–28. http://dx.doi.org/10.3322/canjclin.49.2.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Li, Yingrui, Kang Dong, Xueke Fan, Jun Xie, Miao Wang, Songtao Fu, and Qin Li. "DNT Cell-based Immunotherapy: Progress and Applications." Journal of Cancer 11, no. 13 (2020): 3717–24. http://dx.doi.org/10.7150/jca.39717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Sivori, Simona, Raffaella Meazza, Concetta Quintarelli, Simona Carlomagno, Mariella Della Chiesa, Michela Falco, Lorenzo Moretta, Franco Locatelli, and Daniela Pende. "NK Cell-Based Immunotherapy for Hematological Malignancies." Journal of Clinical Medicine 8, no. 10 (October 16, 2019): 1702. http://dx.doi.org/10.3390/jcm8101702.

Full text

Abstract:

Natural killer (NK) lymphocytes are an integral component of the innate immune system and represent important effector cells in cancer immunotherapy, particularly in the control of hematological malignancies. Refined knowledge of NK cellular and molecular biology has fueled the interest in NK cell-based antitumor therapies, and recent efforts have been made to exploit the high potential of these cells in clinical practice. Infusion of high numbers of mature NK cells through the novel graft manipulation based on the selective depletion of T cells and CD19+ B cells has resulted into an improved outcome in children with acute leukemia given human leucocyte antigen (HLA)-haploidentical hematopoietic transplantation. Likewise, adoptive transfer of purified third-party NK cells showed promising results in patients with myeloid malignancies. Strategies based on the use of cytokines or monoclonal antibodies able to induce and optimize NK cell activation, persistence, and expansion also represent a novel field of investigation with remarkable perspectives of favorably impacting on outcome of patients with hematological neoplasia. In addition, preliminary results suggest that engineering of mature NK cells through chimeric antigen receptor (CAR) constructs deserve further investigation, with the goal of obtaining an “off-the-shelf” NK cell bank that may serve many different recipients for granting an efficient antileukemia activity.

APA, Harvard, Vancouver, ISO, and other styles

37

Coosemans, An, Ignace Vergote, and Stefaan W. Van Gool. "Dendritic cell-based immunotherapy in ovarian cancer." OncoImmunology 2, no. 12 (December 2013): e27059. http://dx.doi.org/10.4161/onci.27059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Akasaki, Yasuharu, Keith L. Black, and John S. Yu. "Dendritic cell-based immunotherapy for malignant gliomas." Expert Review of Neurotherapeutics 5, no. 4 (July 2005): 497–508. http://dx.doi.org/10.1586/14737175.5.4.497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zhong, Hua, Michael R. Shurin, and Baohui Han. "Optimizing dendritic cell-based immunotherapy for cancer." Expert Review of Vaccines 6, no. 3 (June 2007): 333–45. http://dx.doi.org/10.1586/14760584.6.3.333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Schott, Matthias, Werner A. Scherbaum, and Jochen Seissler. "Dendritic Cell-Based Immunotherapy in Thyroid Malignancies." Current Drug Targets - Immune, Endocrine & Metabolic Disorders 4, no. 3 (September 1, 2004): 245–51. http://dx.doi.org/10.2174/1568008043339820.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lorenzo-Herrero, Seila, Alejandro López-Soto, Christian Sordo-Bahamonde, Ana Gonzalez-Rodriguez, Massimo Vitale, and Segundo Gonzalez. "NK Cell-Based Immunotherapy in Cancer Metastasis." Cancers 11, no. 1 (December 28, 2018): 29. http://dx.doi.org/10.3390/cancers11010029.

Full text

Abstract:

Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance.

APA, Harvard, Vancouver, ISO, and other styles

42

Liu, Gang, Magdalena Swierczewska, Gang Niu, Xiaoming Zhang, and Xiaoyuan Chen. "Molecular imaging of cell-based cancer immunotherapy." Molecular BioSystems 7, no. 4 (2011): 993. http://dx.doi.org/10.1039/c0mb00198h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kriegsmann, Katharina, Mark Kriegsmann, Martin Cremer, Michael Schmitt, Peter Dreger, Hartmut Goldschmidt, Carsten Müller-Tidow, and Michael Hundemer. "Cell-based immunotherapy approaches for multiple myeloma." British Journal of Cancer 120, no. 1 (December 6, 2018): 38–44. http://dx.doi.org/10.1038/s41416-018-0346-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Cheng, Min, Yongyan Chen, Weihua Xiao, Rui Sun, and Zhigang Tian. "NK cell-based immunotherapy for malignant diseases." Cellular & Molecular Immunology 10, no. 3 (April 22, 2013): 230–52. http://dx.doi.org/10.1038/cmi.2013.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Motohashi, Shinichiro, and Toshinori Nakayama. "Translational research of NKT cell-based immunotherapy." Folia Pharmacologica Japonica 136, no. 6 (2010): 344–47. http://dx.doi.org/10.1254/fpj.136.344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Jung, Nam-Chul, Jun-Ho Lee, Kwang-Hoe Chung, Yi Sub Kwak, and Dae-Seog Lim. "Dendritic Cell-Based Immunotherapy for Solid Tumors." Translational Oncology 11, no. 3 (June 2018): 686–90. http://dx.doi.org/10.1016/j.tranon.2018.03.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Felzmann, Thomas. "Dendritic cell based immunotherapy in solid tumours." European Journal of Molecular & Clinical Medicine 1 (September 7, 2017): 1. http://dx.doi.org/10.1016/j.nhccr.2017.06.135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Ray, Moumita, Yi-Wei Lee, Joseph Hardie, Rubul Mout, Gulen Yeşilbag Tonga, Michelle E. Farkas, and Vincent M. Rotello. "CRISPRed Macrophages for Cell-Based Cancer Immunotherapy." Bioconjugate Chemistry 29, no. 2 (January 22, 2018): 445–50. http://dx.doi.org/10.1021/acs.bioconjchem.7b00768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Jenne, Lars, Gerold Schuler, and Alexander Steinkasserer. "Viral vectors for dendritic cell-based immunotherapy." Trends in Immunology 22, no. 2 (February 2001): 102–7. http://dx.doi.org/10.1016/s1471-4906(00)01813-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Chakravarti, Deboki, and Wilson W. Wong. "Synthetic biology in cell-based cancer immunotherapy." Trends in Biotechnology 33, no. 8 (August 2015): 449–61. http://dx.doi.org/10.1016/j.tibtech.2015.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!